This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To investigate the topographical distribution of tau pathology and its effect on functional and structural changes in patients with Alzheimer disease (AD) and mild cognitive impairment (MCI) by using 18F-AV-1451 PET.
Methods: We included 20 patients with AD, 15 patients with MCI, and 20 healthy controls, and performed neuropsychological function tests, MRI, as well as 18F-florbetaben (for amyloid) and 18F-AV-1451 (for tau) PET scans. By using the regional volume-of-interest masks extracted from MRIs, regional binding values of standardized uptake value ratios and volumes were measured. We compared regional binding values among 3 diagnostic groups and identified correlations among the regional binding values, performance in each cognitive function test, and regional atrophy.
Results: 18F-AV-1451 binding was increased only in the entorhinal cortex in patients with MCI, while patients with AD exhibited greater binding in most cortical regions. In the 35 patients with MCI and AD, 18F-AV-1451 binding in most of the neocortex increased with a worsening of global cognitive function. The visual and verbal memory functions were associated with the extent of 18F-AV-1451 binding, especially in the medial temporal regions. The 18F-AV-1451 binding also correlated with the severity of regional atrophy of the cerebral cortex.
Conclusions: Tau PET imaging with 18F-AV-1451 could serve as an in vivo biomarker for the evaluation of AD-related tau pathology and monitoring disease progression. The accumulation of pathologic tau is more closely related to functional and structural deterioration in the AD spectrum than β-amyloid.
GLOSSARY
- AD=
- Alzheimer disease;
- ANCOVA=
- analysis of covariance;
- CDR-SB=
- Clinical Dementia Rating–Sum of Boxes;
- EOAD=
- early-onset Alzheimer disease;
- HC=
- healthy control;
- LOAD=
- late-onset Alzheimer disease;
- MCI=
- mild cognitive impairment;
- MMSE=
- Mini-Mental State Examination;
- NFT=
- neurofibrillary tangle;
- PART=
- primary age-related tauopathy;
- PHF=
- paired helical filaments;
- PVE=
- partial volume effect;
- SPM8=
- statistical parametric mapping 8;
- SUV=
- standardized uptake value;
- SUVR=
- standardized uptake value ratio;
- VOI=
- volume-of-interest
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Supplemental data at Neurology.org
- Received November 16, 2015.
- Accepted in final form April 14, 2016.
- © 2016 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Costs and Utilization of New-to-Market Neurologic Medications
Dr. Robert J. Fox and Dr. Mandy Leonard
► Watch
Topics Discussed
Alert Me
Recommended articles
Comparing 18F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
Left frontal connectivity attenuates the adverse effect of entorhinal tau pathology on memory
Regional rates of neocortical atrophy from normal aging to early Alzheimer disease
Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly